{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T12:20:42Z","timestamp":1762604442538,"version":"3.37.3"},"reference-count":19,"publisher":"Georg Thieme Verlag KG","issue":"06","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychiatr Prax"],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>\n          Hintergrund Seit 2017 k\u00f6nnen in Deutschland Cannabisarzneimittel zu Lasten\n                    der Krankenkassen verordnet werden.<\/jats:p><jats:p>\n          Methode \u00c4rztinnen und \u00c4rzte waren zur Teilnahme an einer Begleiterhebung\n                    des Bundesinstituts f\u00fcr Arzneimittel und Medizinprodukte (BfArM) verpflichtet.\n                    Diese Arbeit wertet 16\u2009809 Datens\u00e4tze aus, die zwischen dem 30.03.2017 und dem\n                    31.12.2021 eingingen.<\/jats:p><jats:p>\n          Resultate Die Begleiterhebung erfasste 5582 F\u00e4lle mit psychiatrischer\n                    Diagnose. \u00dcber die H\u00e4lfte der Behandlungen erfolgte mit Dronabinol. 80% der\n                    Behandlungen erfolgten wegen somatoformer St\u00f6rungen. Schmerz war auch bei den\n                    meisten der F\u00e4lle mit anderer psychischer Erkrankung das Zielsymptom. F\u00fcr alle\n                    Diagnosen sch\u00e4tzten die \u00c4rztinnen und \u00c4rzte in mind. 75% der F\u00e4lle die Symptome\n                    als gebessert ein.<\/jats:p><jats:p>\n          Diskussion Die meisten Behandlungen mit Cannabisarzneimitteln bei\n                    psychischen St\u00f6rungen erfolgten wegen Schmerzen. Die Evidenz aus randomisierten\n                    klinischen Studien f\u00fcr psychiatrische Indikationen ist gering.<\/jats:p>","DOI":"10.1055\/a-2296-1358","type":"journal-article","created":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T22:43:06Z","timestamp":1715812986000},"page":"315-320","source":"Crossref","is-referenced-by-count":2,"title":["Cannabisarzneimittel in der Behandlung psychischer St\u00f6rungen \u2013\n                    Befunde aus der Cannabis-Begleiterhebung des Bundesinstituts f\u00fcr Arzneimittel\n                    und Medizinprodukte"],"prefix":"10.1055","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-4139-0861","authenticated-orcid":false,"given":"Felix","family":"W\u00fclfing","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Psychiatrie und Psychotherapie, Charit\u00e9 Universit\u00e4tsmedizin\n                    Berlin Campus Charite Mitte, Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriele","family":"Schmidt-Wolf","sequence":"additional","affiliation":[{"name":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte (BfArM),\n                    Bonn"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Cremer-Schaeffer","sequence":"additional","affiliation":[{"name":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte (BfArM),\n                    Bonn"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathlen","family":"Priebe","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Psychiatrie und Psychotherapie, Charit\u00e9 Universit\u00e4tsmedizin\n                    Berlin Campus Charite Mitte, Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikola","family":"Schoofs","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Psychiatrie und Psychotherapie, Charit\u00e9 Universit\u00e4tsmedizin\n                    Berlin Campus Charite Mitte, Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2024,5,15]]},"reference":[{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.m2021.0125","article-title":"Interim Results of the Survey Accompanying the Prescription of Cannabis-Based\n                    Medicines in Germany Regarding Dronabinol","author":"G Schmidt-Wolf","year":"2021","journal-title":"Dtsch Arztebl Int"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1186\/s12916-022-02459-1","article-title":"Medical cannabinoids: a pharmacology-based systematic review and meta-analysis\n                    for all relevant medical indications","volume":"20","author":"A Bilbao","year":"2022","journal-title":"BMC Med"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1007\/s00115-008-2604-1","article-title":"Neue Schmerzdiagnose in der deutschen ICD-10-Version","volume":"80","author":"W Rief","year":"2009","journal-title":"Nervenarzt"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.psyneuen.2014.11.002","article-title":"The efficacy of nabilone, a synthetic cannabinoid, in the treatment of\n                    PTSD-associated nightmares: A preliminary randomized, double-blind,\n                    placebo-controlled cross-over design study","volume":"51","author":"R Jetly","year":"2015","journal-title":"Psychoneuroendocrinology"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1186\/s12888-023-04818-5","article-title":"Treating nightmares in posttraumatic stress disorder with dronabinol: study\n                    protocol of a multicenter randomized controlled study (THC PTSD-trial)","volume":"23","author":"S Roepke","year":"2023","journal-title":"BMC Psychiatry"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"e0246990","DOI":"10.1371\/journal.pone.0246990","article-title":"The short-term impact of 3 smoked cannabis preparations versus placebo on PTSD\n                    symptoms: A randomized cross-over clinical trial","volume":"16","author":"M O Bonn-Miller","year":"2021","journal-title":"PLoS ONE"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"459","DOI":"10.4088\/JCP.v64n0417","article-title":"Delta 9-Tetrahydrocannabinol (THC) is Effective in the Treatment of Tics in\n                    Tourette Syndrome: a 6-Week Randomized Trial","volume":"64","author":"K R Muller-Vahl","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s00787-021-01899-z","article-title":"European clinical guidelines for Tourette syndrome and other tic\n                    disorders\u2014version 2.0. Part III: pharmacological treatment","volume":"31","author":"V Roessner","year":"2022","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"115135","DOI":"10.1016\/j.psychres.2023.115135","article-title":"CANNA-TICS: Efficacy and safety of oral treatment with nabiximols in adults with\n                    chronic tic disorders - Results of a prospective, multicenter, randomized,\n                    double-blind, placebo controlled, phase IIIb superiority study","volume":"323","author":"K R M\u00fcller-Vahl","year":"2023","journal-title":"Psychiatry Res"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.euroneuro.2017.05.005","article-title":"Cannabinoids in attention-deficit\/hyperactivity disorder: A\n                    randomised-controlled trial","volume":"27","author":"R E Cooper","year":"2017","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref15","first-page":"217","article-title":"Sex and age differences in attention-deficit\/hyperactivity disorder symptoms and\n                    diagnoses: implications for DSM-V and ICD-11","volume":"49","author":"U P Ramtekkar","year":"2010","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.neubiorev.2021.01.022","article-title":"The World Federation of ADHD International Consensus Statement: 208\n                    Evidence-based conclusions about the disorder","volume":"128","author":"S V Faraone","year":"2021","journal-title":"Neurosci Biobehav Rev"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1097\/j.pain.0000000000001464","article-title":"An experimental randomized study on the analgesic effects of\n                    pharmaceutical-grade cannabis in chronic pain patients with fibromyalgia","volume":"160","author":"T Van De Donk","year":"2019","journal-title":"Pain"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejim.2018.01.004","article-title":"Practical considerations in medical cannabis administration and dosing","volume":"49","author":"C A MacCallum","year":"2018","journal-title":"Eur J Intern Med"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1111\/dar.13444","article-title":"Prevalence and correlates of cannabis use disorder among Australians using\n                    cannabis products to treat a medical condition","volume":"41","author":"L Mills","year":"2022","journal-title":"Drug Alcohol Rev"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1477-7517-5-20","article-title":"How high: Quantity as a predictor of cannabis-related problems","volume":"5","author":"N Walden","year":"2008","journal-title":"Harm Reduct J"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1083334","DOI":"10.3389\/fpsyt.2023.1083334","article-title":"Development of cannabis use disorder in medical cannabis users: A 9-month\n                    follow-up of a randomized clinical trial testing effects of medical cannabis\n                    card ownership","volume":"14","author":"M E Cooke","year":"2023","journal-title":"Front Psychiatry"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1159\/000487767","article-title":"International Consensus Statement on Screening, Diagnosis and Treatment of\n                    Substance Use Disorder Patients with Comorbid Attention Deficit\/Hyperactivity\n                    Disorder","volume":"24","author":"C L Crunelle","year":"2018","journal-title":"Eur Addict Res"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"186","DOI":"10.3238\/arztebl.m2022.0389","article-title":"Prescriptions of cannabinoid drugs 2019\u20132022","volume":"120","author":"P Cremer-Schaeffer","year":"2023","journal-title":"Dtsch Arztebl Int"}],"container-title":["Psychiatrische Praxis"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2296-1358.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T16:31:44Z","timestamp":1730824304000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2296-1358"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,15]]},"references-count":19,"journal-issue":{"issue":"06","published-online":{"date-parts":[[2024,9,12]]},"published-print":{"date-parts":[[2024,9]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2296-1358","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0303-4259","1439-0876"],"issn-type":[{"type":"print","value":"0303-4259"},{"type":"electronic","value":"1439-0876"}],"subject":[],"published":{"date-parts":[[2024,5,15]]}}}